Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAEC dose-escalation trial for acute ischaemic stroke
ACTRN12622000588796Phase 2Not yet recruiting
- Sponsor
- Monash Health
- Start
- Sep 2022
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of human amniotic epithelial stem cells in ischemic stroke (3 arms), sponsored by Monash Health. Primary endpoint: Degree of disability after stroke. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ACTRN12622000588796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000588796.